Business

Sunshine Biopharma, Inc. Announced a private placement pricing of $ 8 million in market prices, a Canadian business journal.

Montreal, March 10, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (“Company” or “Sunshine Biopharma”), a pharmaceutical company focused on research, development, and commercialization Oncology and antiviral drug companies today have specific institutional investments Announced that it has signed a securities purchase agreement with homes and accredited investors with a total income of approximately $ 8 million. We will then deduct the placement agents and other recruitment costs we pay.

In connection with this offer, we will issue 3,603,604 units at a purchase price of $ 2.22 per unit, priced in the market under Nasdaq rules. Each unit consists of one common stock or equivalent common stock and one non-trading warrant to purchase one common stock (a total of 3,603,604 shares underlying the warrant). No actual unit is issued at the offering.

The strike price of each warrant is $ 2.22 and is subject to adjustment. The warrant period is 5 years from the date of issue.

The offering will end on or around March 14, 2022, provided that the normal termination conditions are met.

Aegis Capital Corp. is acting as a dedicated deployment agent in connection with this offering.

Additional details regarding the offering are available on Form 8-K, which we submit to the US Securities and Exchange Commission (“SEC”).

The above common and warrant shares are not amended and registered under the Securities Act of 1933 and are offered or sold in the United States unless registered with the US Securities and Exchange Commission (SEC) or have applicable exemptions. You can’t. Such registration requirements. Securities were offered only to accredited investors. In accordance with the registration rights agreement with the investor, we have agreed to submit to the SEC one or more registration statements covering the resale of common stock and shares that can be issued by exercising warrants.

This press release does not constitute an offer to sell or purchase the securities described in this document, and in any state or jurisdiction where such offer, solicitation, or sale is illegal. It will not be sold. Prior to registration or qualification under securities law in such states or jurisdictions.

About Sunshine Biopharma

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is an ongoing COVID-19 that has claimed the lives of more than 6 million people worldwide since its first appearance in December 2019. It is the causative agent of pandemics. Sunshine Biopharma is the development of a treatment for COVID-19, completing the synthesis of four potential inhibitors of PLpro and then identifying the lead compound SBFM-PL4. We are currently developing SBFM-PL4 in collaboration with the University of Georgia Faculty of Pharmaceutical Sciences. In addition, we recently signed a collaborative study with the University of Arizona aimed at assessing the efficacy of the University of Arizona’s three PLpro inhibitors in mice.

In addition, Sunshine Biopharma is working on the development of a unique anti-cancer compound, Adva-27a, to develop a treatment for COVID-19. Tests performed so far have demonstrated the effectiveness of Adva-27a in destroying multidrug-resistant cancer cells, including pancreatic cancer cells, small cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indications will be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property related to Adva-27a.

In addition, Sunshine Biopharma is working on the development of a unique anti-cancer compound, Adva-27a, to develop a treatment for COVID-19. Tests performed so far have demonstrated the effectiveness of Adva-27a in destroying multidrug-resistant cancer cells, including pancreatic cancer cells, small cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indications will be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property related to Adva-27a.

Precautions regarding forward-looking statements

This press release and the relevant management statements of the Company include “Statements on the Future Outlook” (Securities Act 1933 Section 27A and Securities Exchange Act 1934 Section 21E). Defined in). Regarding future events, especially with respect to the offers described in this document. “May”, “Done”, “Expect”, “Plan”, “Intention”, “Plan”, “Believe”, “Predict”, “Expect”, “Expect”, Words such as “estimate” and their variation words and similar expressions are intended to identify forward-looking statements. These statements include known and unknown risks and are based on some assumptions and estimates, which are subject to materially significant uncertainties and contingencies, many of which are within our control. There is no such thing. Actual results, including the expected benefits of the offerings presented herein, may differ materially from those expressed or implied by such forward-looking statements. Factors that may cause significant differences in actual results include, but are not limited to, the risk factors listed in our SEC filings. Our SEC filing is available free of charge from the SEC’s website (www.sec.gov). Except as required by law, we expressly disclaim any obligation or promise to publish any updates or amendments to our forward-looking statements contained in this document, and any changes, events or conditions in our expectations regarding it. Reflects the change in. Or the situation on which the statement is based.

Additional Information:

Sunshine Biopharma Media Contact:
TraDigital IR
Direct phone: 917-633-8980
Investor @ sunshinebiopharma.com

Sunshine Biopharma Inc. Contact:
Camille Sebaaly, CFO
Direct phone: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com


CBJ News Maker

Sunshine Biopharma, Inc. Announced a private placement pricing of $ 8 million in market prices, a Canadian business journal.

Source link Sunshine Biopharma, Inc. Announced a private placement pricing of $ 8 million in market prices, a Canadian business journal.

Related Articles

Back to top button